Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

CNBC's Morgan Brennan shares part of her interview with Forterra CEO Araujo and chief growth officer Scott Sanders on ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Health-care companies fell as a lackluster earnings season for the sector wound down. Shares of vaccine maker Moderna fell after it warned it expects to report a hefty quarterly loss, as recapturing ...

The e-commerce company's Hong Kong stock rallied 6.3% after Bloomberg and Reuters reported that Chinese President Xi Jinping would meet with Alibaba co-founder Jack Ma and other business leaders.

The Dow is falling, and the S&P 500 and Nasdaq are rising Friday as the stock market reacts to news of delays to President Donald Trump's reciprocal tariffs.

The Dow fell and the Nasdaq Composite rose Nasdaq Friday as the stock market reacted to news of delays to President Donald Trump's reciprocal tariffs.